WO2012025831A3 - Salmonella vaccine proteins - Google Patents
Salmonella vaccine proteins Download PDFInfo
- Publication number
- WO2012025831A3 WO2012025831A3 PCT/IB2011/002685 IB2011002685W WO2012025831A3 WO 2012025831 A3 WO2012025831 A3 WO 2012025831A3 IB 2011002685 W IB2011002685 W IB 2011002685W WO 2012025831 A3 WO2012025831 A3 WO 2012025831A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infection
- salmonella spp
- methods
- salmonella vaccine
- vaccine proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Compositions and methods for the treatment or prevention of Gram negative bacterial, such as Salmonella spp. infection, in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate the Salmonella spp. bacterial infection and/or induce an immune response to the protein. Methods for the treatment or prevention of Salmonella spp. infection in a vertebrate are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37661910P | 2010-08-24 | 2010-08-24 | |
US61/376,619 | 2010-08-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012025831A2 WO2012025831A2 (en) | 2012-03-01 |
WO2012025831A3 true WO2012025831A3 (en) | 2012-05-03 |
Family
ID=45723860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/002685 WO2012025831A2 (en) | 2010-08-24 | 2011-08-24 | Salmonella vaccine proteins |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012025831A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
US20100111903A1 (en) * | 2003-09-19 | 2010-05-06 | Emery Daryll A | Compositions produced using enteric pathogens and methods of use |
-
2011
- 2011-08-24 WO PCT/IB2011/002685 patent/WO2012025831A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
US20100111903A1 (en) * | 2003-09-19 | 2010-05-06 | Emery Daryll A | Compositions produced using enteric pathogens and methods of use |
WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
Also Published As
Publication number | Publication date |
---|---|
WO2012025831A2 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012003474A3 (en) | Compositions and methods related to protein a (spa) variants | |
WO2012092469A3 (en) | Clostridium difficile antigens | |
WO2011005341A3 (en) | Compositions and methods related to protein a (spa) variants | |
WO2011152566A3 (en) | Composition for inducing proliferation or accumulation of regulatory t cells | |
WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
MX350325B (en) | Bacterium for use as a probiotic for nutritional and medical applications. | |
SG10201804809RA (en) | Clostridium difficile antibodies | |
WO2009126688A8 (en) | Novel compositions and methods for the treatment of immune related diseases | |
WO2010111641A3 (en) | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis | |
IN2012DN01898A (en) | ||
WO2012097185A3 (en) | Omv vaccine against burkholderia infections | |
CA2821268C (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
AU2018256482A1 (en) | Antibodies Against Clostridium Difficile | |
GB2489382A (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
UA111599C2 (en) | COMPOSITION OF CASPOFUNGIN | |
NZ594019A (en) | Novel antibacterial agents for the treatment of gram positive infections | |
WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
WO2012061248A3 (en) | Novel specific hcv ns3 protease inhibitors | |
WO2013084070A3 (en) | Salmonella vaccine proteins | |
WO2012151279A3 (en) | Induction of il-12 using immunotherapy | |
WO2009115509A3 (en) | Antigenic protein fragments of streptococcus pneumoniae | |
WO2011084967A3 (en) | Methods and compositions for providing protective immunity in the elderly | |
WO2011009042A8 (en) | Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions | |
WO2010132764A3 (en) | Live-attenuated compositions for bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11819485 Country of ref document: EP Kind code of ref document: A2 |